BPC-157 Half-Life: How Long It Stays in Your System
How long BPC-157 stays in the body, how that shapes dosing frequency, and what is known about drug testing.
- Half-life
- less than 30 min
- IV and IM (single and repeated), rat, beagle dog · Frontiers in pharmacology 2022, PMID 36588717
- Dosing interval
- Varies by study
- as used in studies
- WADA
- Prohibited (S0)
- In and out of competition
- Detection window
- 2 findings
- from anti-doping studies, below
BPC-157 half-life
A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.
| Route | Half-life | Measured in | Source |
|---|---|---|---|
| IV and IM (single and repeated) | less than 30 min | Animal · rat, beagle dog | Frontiers in pharmacology 2022, PMID 36588717 |
| not stated (review summary) | less than 30 minutes | Animal · review of preclinical data | HSS journal 2025, PMID 40756949 |
What half-life means
Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.
- A long half-life lets a drug be dosed less often, for example once a week.
- A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
- Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.
What it means for dosing frequency
Dosing intervals used in published studies of BPC-157:
- once daily on 2 consecutive days, intravenous infusion over one hour (Human uncontrolled trial; Alternative therapies in health and medicine 2025, PMID 40131143)
- single procedure, injection around the inflamed bladder area during cystoscopy (Human uncontrolled trial; Alternative therapies in health and medicine 2024, PMID 39325560)
- daily, intraperitoneal (Animal · rat; Joint diseases and related surgery 2026, PMID 42542926)
- single injection 10 min after injury, intraperitoneal (Animal · rat; Journal of orthopaedic surgery and research 2019, PMID 31266512)
Changing the interval changes how much drug builds up between doses, so it is not a free choice.
Drug tests and sport
Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition.
Detection findings from anti-doping analytical studies:
- A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations. · PMID 37959764
- A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days. · PMID 28035768
Tested athletes should treat it as prohibited (s0) at all times.
What the rat and dog studies measured
In rats and beagle dogs given BPC157 by intravenous or intramuscular injection, the unchanged peptide had an elimination half-life of less than 30 min and linear kinetics at every dose tested.[6]
Intramuscular bioavailability averaged approximately 14%-19% in the rats and 45%-51% in the dogs, a wide gap between species.[6]
In these animals the main excretory pathways of BPC157 were urine and bile.[6]
What exists for people
A systematic review of BPC-157 found 36 studies, of which 35 were preclinical and only 1 was clinical.[7]
The same review states that BPC-157 is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys.[7]
FDA's July advisory-committee slides say BPC-157 was not detected in blood plasma after enema administration in two human studies.[12]
For the other routes people use, FDA says the pharmacokinetic profile is unknown: it lists oral, subcutaneous, nasal and transdermal delivery.[12]
Animal numbers from the same slides, after a single intravenous dose: 5.3 minutes in beagle dogs and 15.2 minutes in rats.[12]
What less than 30 minutes implies
Treating 30 minutes as an upper bound, 4 half-lives is 2 hours and leaves at most about 6% of the peptide, and 6 half-lives is 3 hours and leaves at most about 2%; animal-derived, first-order arithmetic only.
Calculated from half life 30 min; after 1 half-lives (30 min) 50.0% of the original amount; after 4 half-lives (120 min) 6.2% of the original amount; after 6 half-lives (180 min) 1.6% of the original amount. Formula: remaining fraction <= 0.5^(minutes / 30)
Drug-testing angle
A doping-control paper on confiscated vials reported that BPC 157 forms a stable metabolite that should be detectable in urine.[5]
Common questions
How long does BPC-157 stay in your system?
In animals, FDA's slides give an intravenous half-life of 5.3 minutes in beagle dogs and 15.2 minutes in rats. For people there is no measured figure for injected, oral or nasal use, and BPC-157 was not detected in plasma after enemas in two studies (see the human-data section above).[12]
What is the half-life of BPC-157?
Animal data give less than 30 min for the parent peptide in rats and dogs; no human measurement is cached.[6]
Is BPC-157 on the WADA prohibited list?
Yes: WADA's S0 class names BPC-157 among its examples.[3]
Does BPC-157 show up on a drug test?
A doping-control paper on confiscated vials reported that BPC-157 forms a stable metabolite that should be detectable in urine. The sources cached here do not address standard workplace drug panels.[5]
More on BPC-157
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Pharmacy Compounding Advisory Committee meeting, 23–24 Jul 2026 (agenda and materials)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 4Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 5Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 7Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025PMID 40756949Accessed 2 Oct 2026
- 8Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 9Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 10Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 11Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats.Journal of orthopaedic surgery and research · 2019PMID 31266512Accessed 2 Oct 2026
- 12Official web pageOfficial web page · web page
Found an error? Report a correction.